ClinicalTrials.gg
Enrolling by invitationNCT07485686IUTICUpdated Mar 20, 2026

Multicentre Prospective Observational Cohort Study Aiming to Collect Medical Data, Create a Database to Facilitate Clinical and Fundamental Research Into Urinary Tract Infections With the Ultimate Goal of Improving Their Treatment.

An observational study in Urinary Tract Infection(UTI), Urinary Tract Infection, Recurrent and UTI - Urinary Tract Infection, sponsored by Angela HUTTNER. Enrolling by invitation at 5 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by Angela HUTTNER · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Urinary Tract Infections with a site in Switzerland — 4 open to participants now, 4 under way, none of them phase 3. Urinary Tract Infections · Switzerland.

Started
2023
the only one that year
Observational
6 of 21
2 open now
Registered
21st of 21
by date
Lead sponsor
1 of 21
Angela HUTTNER

Among the 21 studies in Urinary Tract Infections with a site in Switzerland, this one is the only one that started in 2023, is one of 6 observational ones, and was the 21st registered.

Urinary Tract Infections

808 studies on the registry are indexed under Urinary Tract Infections; 135 are open to participants now.

Browse Urinary Tract Infections studies →

Open to participants now

4 of the 21 studies in Urinary Tract Infections with a site in Switzerland are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 84 Urinary Tract Infections studies recruiting now, 51 (61%) set no upper age limit and 23 (27%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Urinary Tract Infections with a site in Switzerland, or all of them as a file.
02

Study summary

The goal of this prospective observational study is to collect epidemiological, clinical, microbiological, genetic, and behavioral data on individuals with UTIs. The goal is to better understand which interventions are effective and, subsequently, to facilitate studies that will improve our understanding of the condition, enhance patient care and relief, and help combat antimicrobial resistance. This project will enable us to study episodes of urinary tract infections over a period of at least 2 years and up to 5 years.

03

Conditions studied

  • Urinary Tract Infection(UTI)
  • Urinary Tract Infection, Recurrent
  • UTI - Urinary Tract Infection

Keywords

  • uti
  • cohort
  • urinary tract infections
  • observational cohort
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients of any age or disposition (in- or outpatient) with a history of, or active, urinary symptoms suggestive of UTI or diagnosed with UTI are eligible for inclusion into SUTIC. Adult (≥18 years) sexual partners of included patients are also eligible.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Urinary symptoms/signs suggestive of UTI (as determined by investigators), or a history of such symptoms/signs.

Exclusion criteria

Exclusion Criteria:

  • Unwillingness to provide (for patients with capacity or for the representatives of those without capacity) and/or inability to provide informed consent (for patients without capacity and without representation).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Total number of suspected and microbiologically confirmed urinary tract infections.

    Yearly incidence of suspected and microbiologically confirmed UTI at 12 months among all patients initially presenting with lower urinary tract symptoms (LUTS) or upper urinary tract symptoms (UUTS).

    Time frame: From enrollment for a minimum of two years and a maximum of five years, with data collection at regular time points (2 months, 6 months, 12 months, 18 and 24 months after enrollment)

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Dec 2028, 66 months after the start.

Of 72 non-industry observational studies under Urinary Tract Infections, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's planned 66 months is above that.

Counting every sponsor, half of 84 studies reached it within 26 months; a quarter within 11 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2026
First posted
Mar 20, 2026
StartActual
Jun 6, 2023
Primary completionEst.
Dec 2028
CompletionEst.
Jan 2029
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07485686
Lead sponsor
Angela HUTTNER
Responsible party
Angela HUTTNER (Professor, Attending physician, Division of Infectious Diseases, University of Geneva, Switzerland) — Sponsor-investigator
First posted
Mar 20, 2026
Start date
Jun 6, 2023
Primary completion
Dec 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Mar 20, 2026

Study contacts

Angela Huttner, MD
principal investigator · Geneva University Hospitals, Geneva Faculty of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion